Benitec Biopharma Inc. (BNTC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BNTC currently has 34.4M outstanding shares. with significant dilution risk as 175M authorized shares could dilute existing holders by 510.8%. The company has significantly diluted shareholders by 168.9% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 34.4M shares outstanding |
34M | 180M |
| Jan 30, 2026 |
S-3 filing: This prospectus relates to the resale by the Selling Stockholders named in this prospectus of 1,481,481 shares of common stock of Benitec Biopharma Inc. |
34M | 180M |
| Nov 14, 2025 |
10-Q filing | 33.9M shares outstanding |
34M | 170M |
| Sep 22, 2025 |
10-K filing | 26.3M shares outstanding |
26M | 170M |
| May 23, 2025 |
S-3 filing: This prospectus relates to the resale by the Selling Stockholders named in this prospectus of 900,000 shares of common stock of Benitec Biopharma Inc. |
26M | 170M |
| May 14, 2025 |
10-Q filing | 25.6M shares outstanding |
26M | 170M |
| Feb 14, 2025 |
10-Q filing | 22.1M shares outstanding |
22M | 170M |
| Nov 14, 2024 |
10-Q filing | 23.2M shares outstanding |
23M | 170M |
| Nov 01, 2024 |
S-3 filing: The company may offer common stock, debt securities, warrants or units consisting of all or some of such securities having an aggregate offering price of up to $125,000,000. |
11M | 170M |
| Sep 26, 2024 |
10-K filing | 10.6M shares outstanding |
11M | 170M |
| May 16, 2024 |
S-1 filing: This prospectus relates to the resale by the Selling Stockholders of shares of common stock of Benitec Biopharma Inc. |
9.4M | 170M |
| May 13, 2024 |
10-Q filing | 9.4M shares outstanding |
9.4M | 140M |
| Feb 23, 2024 |
S-3 filing: The company intends to offer common stock, debt securities, warrants or units, separately or in combination, up to an aggregate offering price of $125,000,000. |
2.6M | 140M |
| Feb 13, 2024 |
10-Q filing | 2.6M shares outstanding |
2.6M | 140M |
| Nov 13, 2023 |
10-Q filing | 2.6M shares outstanding |
2.6M | 140M |
| Sep 21, 2023 |
10-K filing | 2.5M shares outstanding |
2.5M | 140M |
| Aug 07, 2023 |
S-1/A filing: This S-1/A filing describes an offering of 10,309,278 shares of common stock, pre-funded warrants to purchase 10,309,278 shares of common stock, and common warrants to purchase 10,309,278 shares of common stock. |
1.6M | 140M |
| Aug 03, 2023 |
S-1/A filing: The company is offering shares of common stock, pre-funded warrants, and common warrants. |
1.6M | 140M |
| Jul 31, 2023 |
S-1/A filing: This S-1/A filing relates to an offering of 4,424,778 shares of common stock and pre-funded warrants to purchase common stock, with an option for the underwriter to purchase additional shares. |
1.6M | 110M |
| Jul 07, 2023 |
S-1 filing: The filing is an S-1 for an offering of common stock and pre-funded warrants to purchase shares of common stock. |
28M | 110M |
| May 15, 2023 |
10-Q filing | 28.0M shares outstanding |
28M | 110M |
| Feb 13, 2023 |
10-Q filing | 27.6M shares outstanding |
28M | 110M |
| Dec 13, 2022 |
S-1 filing: The company is offering 29,809,471 shares of its common stock issuable upon exercise of outstanding warrants (the Series 2 Common Warrants) that were issued in a public offering completed on September 15, 2022, with an exercise price of $0.66 per share, exercisable through December 9, 2027. |
28M | 110M |
| Nov 10, 2022 |
10-Q filing | 28.0M shares outstanding |
28M | 79M |
| Sep 12, 2022 |
S-1/A filing: This S-1/A filing relates to an offering of 25,380,710 shares of common stock, pre-funded warrants to purchase 25,380,710 shares of common stock, and common warrants to purchase 25,380,710 shares of common stock. |
8.2M | 79M |
| Sep 09, 2022 |
S-1/A filing: This is an S-1/A filing for an offering of common stock, pre-funded warrants, and common warrants. |
8.2M | 79M |
| Sep 02, 2022 |
10-K filing | 8.2M shares outstanding |
8.2M | 54M |
| Aug 10, 2022 |
S-1/A filing: This is an S-1/A filing for a warrant agency agreement related to a registered offering of common stock, pre-funded warrants, and Series 1 and Series 2 warrants. |
8.2M | 54M |
| Aug 08, 2022 |
S-1/A filing: This S-1/A filing relates to the offering of 25,300,442 shares of common stock together with common warrants to purchase shares of our common stock and pre-funded warrants. |
8.2M | 54M |
| Jul 29, 2022 |
S-1 filing: The company is offering shares of common stock, common warrants to purchase shares of common stock, and pre-funded warrants to purchase shares of common stock. |
8.2M | 3.3M |
| May 16, 2022 |
10-Q filing | 8.2M shares outstanding |
8.2M | 3.3M |
| Feb 14, 2022 |
10-Q filing | 8.2M shares outstanding |
8.2M | 3.3M |
| Nov 15, 2021 |
10-Q filing | 8.2M shares outstanding |
8.2M | 3.3M |
| Sep 20, 2021 |
10-K filing | 8.2M shares outstanding |
8.2M | 3.3M |
| May 12, 2021 |
10-Q filing | 7.9M shares outstanding |
7.9M | 3.3M |
| Feb 18, 2021 |
S-3 filing: The company filed an S-3 form to register a shelf offering of common stock, debt securities, warrants or units with an aggregate offering price of up to $75,000,000. |
4.8M | 3.3M |
| Feb 09, 2021 |
10-Q filing | 4.5M shares outstanding |
4.5M | 3.3M |
| Nov 13, 2020 |
10-Q filing | 4.4M shares outstanding |
4.4M | 3.3M |
| Oct 01, 2020 |
S-1/A filing: This S-1/A filing includes the offering of 1,666,666 shares of common stock, as well as pre-funded warrants to purchase 1,666,666 shares of common stock, with the underlying shares also being offered. |
1.1M | 3.3M |
| Sep 23, 2020 |
10-K filing | 1.1M shares outstanding |
1.1M | 0 |
| Aug 14, 2020 |
S-1 filing: This S-1 filing is for an offering of common stock and pre-funded warrants. The last reported sale price of our common stock on The Nasdaq Capital Market was $8.31 on August 13, 2020. |
1.1M | 0 |